ESR1 and breast carcinoma: Among the most pressing issues is acquiring a greater understanding of endocrine resistance, whether de novo (some ER+ tumors never respond to an endocrine intervention) or acquired resistance (many ER+ breast cancers recur decades after an apparently successful treatment).